- Home
- CAN vs CHRS Comparison
CAN vs CHRS Comparison
Compare CAN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | CHRS |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.8M | 177.7M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CAN | CHRS |
|---|---|---|
| Price | $0.36 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.21 | ★ $5.51 |
| AVG Volume (30 Days) | ★ 11.9M | 1.1M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | $63.64 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $1.09 |
| 52 Week High | $2.22 | $2.62 |
Technical Indicators
Market Signals| Indicator | CAN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 72.23 | 56.44 |
| Support Level | $0.31 | $1.34 |
| Resistance Level | $0.36 | $1.48 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 88.27 | 77.22 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.